Author:
Higashi Sena,Nakabori Tasuku,Mukai Kaori,Seiki Yusuke,Watsuji Ko,Hirao Takeru,Kawamoto Yasuharu,Urabe Makiko,Kai Yugo,Takada Ryoji,Yamai Takuo,Ikezawa Kenji,Uehara Hiroyuki,Ohkawa Kazuyoshi
Abstract
<b><i>Introduction:</i></b> Portal vein aneurysm (PVA) is a rare saccular or fusiform portal vein dilatation. The management and optimal treatment of PVA remain unknown. <b><i>Case Presentation:</i></b> A 53-year-old man with hepatitis C virus (HCV) infection was diagnosed with PVA measuring 28 mm in diameter. Under observation, his liver fibrosis progressed, and the PVA diameter gradually increased to 52 mm. The patient was treated with elbasvir-grazoprevir for 12 weeks, and HCV disappeared. After achieving sustained virological response, liver fibrosis improved and the PVA progression ceased. <b><i>Conclusion:</i></b> HCV clearance by direct-acting antiviral treatment not only regressed liver fibrosis but may have also restrained the progression of PVA in a patient with cirrhosis type C and PVA.